A slowly progressive inflammation of the glomeruli characterized by immune complex deposits at the glomerular basement membrane, resulting in a thickened membrane, and nephrotic syndrome.
Comprehensive, easy-to-understand information about this condition
How we create this content →Documentation on membranous glomerulonephritis is limited due to its rarity, affecting fewer than 10,000 people in the United States. This rarity restricts the scope of systematic clinical studies and comprehensive documentation. Additionally, the lack of identified genetic factors and established inheritance patterns complicates the understanding of the condition, making it difficult to characterize clinically.
To navigate your care effectively, consider consulting a nephrologist with specific expertise in glomerular diseases. This specialist can provide tailored management strategies for membranous glomerulonephritis. Additionally, you may want to explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org for support and information. Participating in clinical trials could also be beneficial; keep an eye on the active trials listed on ClinicalTrials.gov.
Several orphan drugs are currently in development for membranous glomerulonephritis, including Budoprutug, Corticotropin (ACTH) porcine (synthetic), felzartamab, Mizoribine, obinutuzumab, rituximab, and zanubrutinib. There are also 60 active clinical trials exploring various aspects of this condition. You can find more information about these trials at ClinicalTrials.gov by searching for 'membranous glomerulonephritis'.
Actionable guidance for navigating care for membranous glomerulonephritis
To navigate your care effectively, consider consulting a nephrologist with specific expertise in glomerular diseases. This specialist can provide tailored management strategies for membranous glomerulonephritis. Additionally, you may want to explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org for support and information. Participating in clinical trials could also be beneficial; keep an eye on the active trials listed on ClinicalTrials.gov.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on membranous glomerulonephritis is limited due to its rarity, affecting fewer than 10,000 people in the United States. This rarity restricts the scope of systematic clinical studies and comprehensive documentation. Additionally, the lack of identified genetic factors and established inheritance patterns complicates the understanding of the condition, making it difficult to characterize clinically.
To navigate your care effectively, consider consulting a nephrologist with specific expertise in glomerular diseases. This specialist can provide tailored management strategies for membranous glomerulonephritis. Additionally, you may want to explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org for support and information. Participating in clinical trials could also be beneficial; keep an eye on the active trials listed on ClinicalTrials.gov.
Several orphan drugs are currently in development for membranous glomerulonephritis, including Budoprutug, Corticotropin (ACTH) porcine (synthetic), felzartamab, Mizoribine, obinutuzumab, rituximab, and zanubrutinib. There are also 60 active clinical trials exploring various aspects of this condition. You can find more information about these trials at ClinicalTrials.gov by searching for 'membranous glomerulonephritis'.
Actionable guidance for navigating care for membranous glomerulonephritis
To navigate your care effectively, consider consulting a nephrologist with specific expertise in glomerular diseases. This specialist can provide tailored management strategies for membranous glomerulonephritis. Additionally, you may want to explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org for support and information. Participating in clinical trials could also be beneficial; keep an eye on the active trials listed on ClinicalTrials.gov.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Documentation on membranous glomerulonephritis is limited due to its rarity, affecting fewer than 10,000 people in the United States. This rarity restricts the scope of systematic clinical studies and comprehensive documentation. Additionally, the lack of identified genetic factors and established inheritance patterns complicates the understanding of the condition, making it difficult to characterize clinically.
To navigate your care effectively, consider consulting a nephrologist with specific expertise in glomerular diseases. This specialist can provide tailored management strategies for membranous glomerulonephritis. Additionally, you may want to explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org for support and information. Participating in clinical trials could also be beneficial; keep an eye on the active trials listed on ClinicalTrials.gov.
Several orphan drugs are currently in development for membranous glomerulonephritis, including Budoprutug, Corticotropin (ACTH) porcine (synthetic), felzartamab, Mizoribine, obinutuzumab, rituximab, and zanubrutinib. There are also 60 active clinical trials exploring various aspects of this condition. You can find more information about these trials at ClinicalTrials.gov by searching for 'membranous glomerulonephritis'.
Actionable guidance for navigating care for membranous glomerulonephritis
To navigate your care effectively, consider consulting a nephrologist with specific expertise in glomerular diseases. This specialist can provide tailored management strategies for membranous glomerulonephritis. Additionally, you may want to explore resources such as the National Organization for Rare Disorders (NORD) at rarediseases.org for support and information. Participating in clinical trials could also be beneficial; keep an eye on the active trials listed on ClinicalTrials.gov.
Consider asking your healthcare providers these condition-specific questions
Helpful links for rare disease information and support
Clinical profile data for this condition is not yet available. Phenotype information may still be loading below.
Research studies investigating treatments and therapies for this condition.
Active Trials
Total Trials
Data from ClinicalTrials.gov Jan 30, 2026
Consider asking your healthcare providers these condition-specific questions
AI-Generated Content: This summary was generated using AI. Content has been fact-checked. Always consult with qualified healthcare providers for medical guidance.
Organizations with approved therapies for this disease
No approved therapies yet
Research is ongoing — 8 companies have orphan drug designations for this disease
Kisho delivers this disease record via API, including phenotypes (HPO), genes, orphan drug designations, screening status, and PAG mapping, with version history and governance.